Emergency Management of Agitation in Schizophrenia
Overview
Authors
Affiliations
Schizophrenia is a common psychiatric condition, affecting approximately 1% of the population. Acute emergent presentations often include hallucinations, delusions, thought, and speech disorders. Agitation is common among emergency patients with schizophrenia. Decisional capacity should be assessed in all patients. Reversible causes of agitation should be ruled out, including infection, metabolic disorders, endocrine disorders, trauma, pain, noncompliance, toxicological disorders, and structural brain abnormalities. Agitation may be managed acutely using a combination of pharmacological agents and nonpharmacological interventions. Effective pharmacological agents include several classes of antipsychotic agents and benzodiazepines. Potential life-threatening complications of pharmacological therapy should be anticipated, which may include neuroleptic malignant syndrome (NMS), prolonged QT syndrome, and respiratory depression. Nonpharmacological interventions may include a quiet environment, physical restraints, and behavioral interventions. Disposition decisions should be made based on the etiology of agitation, effective management, decisional capacity, and presence of suicidal or homicidal intentions. Many patients who have required nonpharmacological or pharmacological management of agitation require inpatient psychiatric treatment, either voluntarily or involuntarily. Psychiatric consultation should be sought for patients with schizophrenia and uncertain disposition determinations, or those requiring other complex management decisions.
Li Z, Ren H, Tian Y, Zhou J, Chen W, OuYang G Front Psychiatry. 2024; 15:1472671.
PMID: 39435128 PMC: 11491364. DOI: 10.3389/fpsyt.2024.1472671.
Guarro Carreras M, Jimenez Suarez L, Lago Garcia L, Montes Reula L, Neyra Del Rosario A, Rodriguez Batista F Drugs Context. 2024; 13.
PMID: 39131604 PMC: 11313206. DOI: 10.7573/dic.2024-4-4.
Gonzalez-Rodriguez A, Seeman M, Roman E, Natividad M, Pages C, Ghigliazza C Healthcare (Basel). 2023; 11(4).
PMID: 36832992 PMC: 9956049. DOI: 10.3390/healthcare11040458.
Garrote-Camara M, Santolalla-Arnedo I, Ruiz de Vinaspre-Hernandez R, Gea-Caballero V, Sufrate-Sorzano T, Pozo-Herce P Front Psychol. 2021; 12:779277.
PMID: 34955998 PMC: 8693627. DOI: 10.3389/fpsyg.2021.779277.
Pompili M, Ducci G, Galluzzo A, Rosso G, Palumbo C, de Berardis D Int J Environ Res Public Health. 2021; 18(8).
PMID: 33924111 PMC: 8074323. DOI: 10.3390/ijerph18084368.